Texas Medical Board Rules: Biologic Administration

Under Texas Medical Board rules for regenerative biologic therapy administration, licensed physicians must conduct the initial patient evaluation, establish explicit written delegation protocols for mid-level staff, and maintain strict adherence to FDA 21 CFR Part 1271 HCT/P standards. Structuring compliant clinical workflows around diagnosis, informed consent, and non-physician supervision protects Texas medical practices from regulatory audits while expanding advanced biologics patient care. This operational framework outlines the delegation limits, documentation rules, and risk-mitigation strategies required for Texas practice managers and medical directors.

The Texas Medical Board Framework for Biologic Therapy

The Texas Medical Board regulates the practice of medicine to ensure patient safety across all therapeutic interventions, including non-surgical orthopedics, aesthetics, and interventional pain management. When integrating regenerative biologics into a practice, administrators must address three primary regulatory pillars: physician oversight, delegation parameters, and informed consent.

Physician Evaluation and Prescriptive Authority

Under TMB regulations, the administration of biologic agents—such as platelet-rich plasma (PRP), Wharton's jelly allografts, amniotic fluid, and exosomes—is considered the practice of medicine. A licensed Texas physician must establish a valid physician-patient relationship prior to initiating therapy. This requires:

• Conducting an in-person or compliant telemedicine physical evaluation.
• Establishing a definitive diagnosis and clinical rationale for biologic administration.
• Outlining a comprehensive treatment plan that details the specific biologic modality to be utilized.

Delegation to Advanced Practice Providers

Many practices utilize Advanced Practice Registered Nurses (APRNs) or Physician Assistants (PAs) to administer biologic procedures. TMB Chapter 193 outlines explicit rules governing delegation:

• Prescriptive Authority Agreements (PAAs): PAs and APRNs must operate under a formal PAA signed by the delegating physician. The agreement must delineate the scope of delegated procedures, including specific injection protocols.
• Quality Assurance Meetings: The delegating physician and mid-level provider must document regular, recurring chart reviews and quality assurance meetings as prescribed by state regulations.
• Supervision Requirements: While direct physical presence of the physician is not required for every delegated administration in standard outpatient settings, the delegating physician remains legally responsible for the patient's care and must be readily available for consultation.

FDA Regulatory Alignment for Texas Practices

State medical boards evaluate compliance within the broader context of federal law. Practices administering regenerative biologics must ensure that the products they procure and apply align with Food and Drug Administration (FDA) guidelines under 21 CFR Part 1271.

361 HCT/Ps vs. 362 Biologics

To remain compliant without an Investigational New Drug (IND) application or Biologics License Application (BLA), human tissue products must fall under Section 361 of the Public Health Service Act. Section 361 criteria dictate that the product must be:

1. Minimally Manipulated: The processing of the tissue cannot alter the original relevant biological characteristics.
2. Intended for Homologous Use: The tissue must perform the same basic function in the recipient as it performed in the donor (e.g., structural support, cushioning, or covering).
3. Non-Systemic: The product must not rely on the metabolic activity of living cells for its primary function, unless used for autologous application or specified biological relationships.

Procuring non-compliant tissue products exposes the practice to administrative sanctions from both federal regulators and the Texas Medical Board. Reviewing manufacturer documentation and donor screening protocols before adding a line to your formulary is a fundamental procurement safeguard. Further operational guidance on sourcing can be found in our FAQ section.

Administrative and Operational Compliance Checklist

To standardize operations and prepare for administrative audits, medical practice managers should implement a structured compliance checklist across all clinical sites:

• Physician Evaluation Documentation: Verify that an explicit diagnostic note and clinical justification exist in the EHR prior to procedure scheduling.
• Customized Informed Consent Forms: Utilize consent documents that explicitly outline the biologic source (e.g., autologous blood derivative vs. human umbilical cord tissue allograft), off-label status where applicable, potential risks, and alternative standard-of-care options.
• Delegation Agreements: Maintain signed, updated Prescriptive Authority Agreements on-site for all participating APRNs and PAs, including logged QA chart reviews.
• Chain of Custody and Lot Tracking: Record the manufacturer name, product description, lot number, expiration date, donor ID, and exact administration site in the patient's medical record for every procedure.
• Cold Chain Maintenance Logs: Implement automated or manual daily logbooks for ultra-low freezers (-80°C) storing cryopreserved allografts, ensuring compliance with tissue bank storage parameters.
• Adverse Event Protocols: Establish clear internal reporting guidelines for tracking and managing post-procedure complications, infection control, or unexpected tissue reactions.

Clinical Considerations for Texas Physicians

While practice managers focus on workflow, procurement, and documentation, treating clinicians must ensure that clinical execution adheres to established standards of care.

Patient Selection and Diagnostic Workup

Clinical success and medical board compliance begin with rigorous patient selection. Physicians evaluating candidates for regenerative biologics should perform complete structural and functional assessments. Utilizing objective diagnostic tools—such as musculoskeletal ultrasound, MRI, or targeted lab panels—establishes clear baseline metrics and supports medical necessity.

Precision Administration and Guidance

To maximize clinical outcomes and minimize risk, regenerative biologics should be administered using precise imaging guidance (ultrasound or fluoroscopy) when treating deep anatomical structures, joint spaces, or tendinous insertions. Accurate placement reduces post-procedure discomfort and optimizes tissue integration.

Post-Procedure Care and Monitoring

Clinicians must establish standardized post-administration follow-up intervals (typically at 2 to 4 weeks, 6 weeks, and 12 weeks). These visits document functional progress, visual analog scale (VAS) pain scores, and adverse events, ensuring a complete clinical record that validates the efficacy and safety of the intervention.

What This Means for Your Practice

To ensure your facility operates seamlessly within Texas Medical Board parameters while optimizing administrative efficiency, management should take immediate action in three key areas:

1. Conduct an Oversight Audit: Review all current APRN and PA protocols to verify that delegation agreements explicitly cover the specific biologic procedures being performed in your clinic.
2. Standardize EHR Documentation Templates: Implement mandatory fields within your electronic health record system for donor lot tracking, storage temperature verification, and detailed informed consent signatures.
3. Audit Sourcing Vendors: Confirm that every biologic product supplier provides complete Certificates of Analysis (CoAs), tissue bank registration numbers, and third-party sterility testing documentation.

Operationalizing Compliance with Sourcing Partners

Building a compliant, high-performing regenerative service line requires robust alignment between your administrative team, clinical staff, and supplier network. Working alongside specialized distributors who understand state-level regulatory nuances ensures your practice maintains access to high-quality, compliant products designed for seamless integration.

For regenerative medicine doctors seeking to enhance clinical protocols, optimize supply chains, or evaluate compliant tissue allografts and hardware platforms, direct collaboration with experienced distribution advisors is essential.

To review compliant product portfolios, access educational resources, or schedule a comprehensive workflow consultation for your clinic, contact Dallas Regenerative Solutions today.